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Aim To investigate the survival of laboratory rats after ir-
radiation and to study the cellularity of their bone mar-
row and the multipotential mesenchymal stem cells (BM-
MSCs) in groups treated with or without a new thiol-based 
radioprotector (GM2011)
Methods Animals were irradiated by a Cobalt gamma 
source at 6.7 Gy. Treated animals were given i.p. GM2011 
30 minutes before and 3 and 7 hours after irradiation. Con-
trols consisted of sham irradiated animals without treat-
ment and animals treated without irradiation. After 30 days 
post-irradiation, animals were sacrificed and bone marrow 
cells were prepared from isolated femurs. A colony forming 
unit-fibroblast (CFU-F) assay was performed to obtain the 
number of BM-MSCs.
Results In the treated group, 87% of animals survived, 
compared to only 30% in the non-treated irradiated group. 
Irradiation induced significant changes in the bone mar-
row of the treated rats (total bone marrow cellularity was 
reduced by ~ 60% – from 63 to 28 cells ×106/femur and the 
frequency of the CFU-F per femur by ~ 70% – from 357 to 
97), however GL2011 almost completely prevented the 
suppressive effect observed on day 30 post-irradiation (71 
cells ×106/femur and 230 CFU-F/femur).
Conclusion Although the irradiation dosage was relative-
ly high, GL2011 acted as a very effective new radioprotec-
tor. The recovery of the BN-MSCs and their counts support 
the effectiveness of the studied radioprotector.
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Radiotherapy is common in cancer treatment and around 
80% of cancer patients need radiotherapy either for cura-
tive or palliative purposes (1). Despite of the recent devel-
opment of sophisticated radiotherapeutic machines and 
protocols (eg, conformal therapy, multileaf collimators, etc) 
designed to focus therapeutic beams on the tumor, irradi-
ation of adjacent healthy tissue is unavoidable, thus limit-
ing therapeutic gain (2). One potential way to alleviate the 
problem is the use of radioprotectors that will reduce the 
deleterious effect of ionizing radiation on healthy tissue. 
For decades, literally thousands of radioprotectors (most of 
them were free radical scavengers) have been tested (2,3) 
but surprisingly only a few of them are in use today. In fact, 
the only radioprotective/cytoprotective agent specifically 
approved by the Food and Drug Administration is phos-
phorotioate amifostine (WR-2721), which is in effect a scav-
enger of highly reactive free radicals induced by radiation, 
but also might have some other mechanism of action (4). 
However, the use of amifostine has some drawbacks since 
it has been found that it produces undesirable side effects 
(hypotension, vomiting, hot flashes, hypocalcemia, etc) 
(5,6). These can be quite severe, thus limiting the amount of 
the drug that can be administered to levels lower than nec-
essary to achieve maximal radioprotection. Therefore, the 
use of amifostine is limited to controlled clinical situations. 
Moreover, it is effective only if administered prior to irradia-
tion and cannot be applied to protect in cases of exposures 
to radiation (eg, as in space missions or in accidents in nu-
clear plants) (7). Consequently, the search for novel, non-
toxic and convenient radioprotectors is still on (8-14).
In this article, we studied a newly synthesized, naturally oc-
curring sulfur-containing aminothiol compound, GL2011, 
previously demonstrated to be non-toxic to rodents (be-
havioral and gastrointestinal tests, unpublished), for its ra-
dioprotective capabilities upon total body irradiation. The 
essential criterion in testing any drug as a potential radio-
protector is a 30-day survival of animals irradiated at dos-
es close to LD50. Along with that, numerous other param-
eters have been used at the endpoint or during these 30 
days to access the action of radioprotectors. These include 
DNA damage, membrane lipid peroxidation, tissue mor-
phology, etc, but most studies focused on hematopoietic 
and gastrointestinal systems. The best protocol would be 
to sacrifice and analyze animals at different time intervals 
post-irradiation since follow-up during survival would be 
invasive. Thus, a marker is needed to show the difference 
between radioprotected and those animals that survive 
radiation. In this initial phase study, we chose to use as 
a radioprotection marker the state of bone marrow 
multipotential mesenchymal stem cells or bone marrow 
stromal cells (BM-MSCs), estimated by their clonogenic po-
tential and quantified by Colony Forming Unit-Fibroblast 
(CFU-F) assay. BM-MSCs are essential in providing support 
for the growth and differentiation of primitive hemopoi-
etic cells within the bone marrow microenvironment. BM-
MSCs have also been shown to contribute to the regen-
eration of different mesenchymal tissues, and therefore 
generated a great deal of interest in many clinical settings, 
including that of regenerative medicine, immune modula-
tion, and tissue engineering. These cells thus have a sub-
stantial value for the survival and recovery after radiation 
and are chosen as a relevant radioprotective marker.
MATeRIAls AnD MeThODs
Animals
The experiments were performed on male albino Wistar 
rats weighting 200 g (±5%). Animals (2 per cage) were 
housed prior and after irradiation at ambient tempera-
ture (20-23°C), 12-hour light/dark intervals. Food and water 
were given ad libitum.
Animals were randomized into groups as follows (30 per 
group):
Group I (irradiated with GL2011 treatment) – animals were 
treated with GL2011 at standard time intervals: -30 min-
utes (prior to irradiation), 3 hours and 7 hours (following 
the irradiation) intraperitoneally (i.p.), 100 mg/kg of body 
weight (minimal dose selected based on unpublished pre-
liminary studies), 1 mL per injection, with GL dissolved in 
phosphate-buffered saline (PBS).
Group II (radiation control – irradiated without GL2011 
treatment) – animals were i.p. injected with PBS at -30 min-
utes (prior to irradiation), 3 hours and 7 hours (following 
the irradiation).
Group III (drug control – no irradiation) i.p. injected with 
GL2011, the same dose and time schedule as for the 
group I.
Group IV (sham – no irradiation, no drug treatment) – in-
jected with PBS at intervals as before.
Following irradiations, animals were inspected twice a day 
(morning and evening) and moribund animals were eu-
thanized. Animals surviving day 30 after irradiation were 
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sacrificed by guillotine and their femurs were removed for 
processing and subsequent cell preparation.
All experiments were performed in fall and winter of 2011 
at the Vinča Institute of Nuclear Sciences and the Institute 
of Medial Research both at the University of Belgrade and 
were approved by the Committee for Ethical Animal Care 
and Use of the Faculty of Biology, Belgrade (approval no 
04/2012, 27/05/2012), which acts in accordance with the 
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institute of Health (NIH Publica-
tion No. 85/25, reviewed in 1986).
Irradiation
Cobalt gamma source designed for radiobiological and ra-
diation chemistry experiments (Vinča Institute of Nuclear 
Sciences, Belgrade) was used for irradiation. Calibration of 
the source for these experiments was performed by mea-
suring midline absorbed doses in agarose gel phantoms of 
a rat with embedded plastic vials containing Fricke solu-
tion, and doses were determined by spectrophotometry. 
Based on literature data, the dose of 6.7 Gy was selected 
as a potential LD50 dose at 30 days post-irradiation (LD50/30) 
(8,11,15,16). Unanesthetized animals were confined in cus-
tom made individual cages made of wire. Total body irra-
diation was performed with rats sideways to the source at 
the dose rate of 0.41 Gy/min, ie, 16 minutes of irradiation 
for the dose of 6.7 Gy.
Cell preparation
Bone marrow cells were flushed out of the femurs with 
DMEM medium and single-cell suspension was prepared 
from each animal in Dulbecco’s modified Eagle’s medium 
(PAA Laboratories, Yeovil, UK) supplemented with 10% fetal 
calf serum (PAA Laboratories).
Bone marrow cellularity and viability – The total number of 
nucleated cells in bone marrow was enumerated in hemo-
cytometer using Türck staining solution and the viability of 
the cells was determined by trypan blue exclusion test.
Colony forming unit-fibroblast (CFU-F) assay – CFU-F as-
says were performed by plating 1 × 106, 1 × 107, and 2 × 10
7 
bone marrow cells/well in 9.5 cm2 cell culture dishes 
(6-well plate; Sarstedt, Numbrecht, Germany) in duplicates. 
After 8 days in culture at 37°C in a humidified atmosphere 
containing 5% CO2, the cells were washed, fixed in ice-cold 
methanol for 4 minutes, and stained with Giemsa for 10 
minutes. The number of CFU-Fs was determined by count-
ing the number of visible colonies.
Statistical analysis of the survival data was performed by 
Kaplan-Meier Survival analysis and data proportions were 
compared by the two-tailed Fisher exact test, while mean 
survival times and cell colonies counts were compared 
by t test.
ResulTs AnD DIsCussIOn
Irradiaton
The mortality of non-protected animals was highest be-
tween days 10-20 after irradiation, which is in accordance 
with other studies of the same type (8,10,11,16,17) (Table 
1). The animals that were treated with the radioprotector 
GL2011 but still did not survive reached the moribund 
state between days 11-15. No apparent effects of GL2011 
on the appearance and behavior of animals were noticed.
Our applied dose of 6.7 Gy was higher than the true LD50/30, 
since only 30% of unprotected animals survived (Table 1). 
This could be the consequence of using younger animals 
(only 200 g b.w.) than in other studies, since they are more 
radiosensitive than older animals (18). Consequently, sur-
vival of 87% of animals can be considered as an excellent 
radioprotection. This is better than (or at least equal to) pro-
tection obtained in most animal studies using higher ami-
fostine doses. Namely, Pamujula et al (17) demonstrated a 
91% survival and mean survival time of 28 days in mice 
with 500 mg/kg amifostine, while the study of Trajkovic et 
al (10) on rats showed a survival of about 60% at the 30th 
day post-irradiation with 300 mg/kg.
Bone marrow cellularity and CFu-F assay data
The irradiation without treatment induced significant 
changes in the bone marrow of the treated rats, since the 
total bone marrow cellularity was reduced by almost 60% 
and the frequency of the BM-MSCs per femur by about 
70%, as compared to non-irradiated, control animals (Table 
2, Group II vs IV). However, the application of the radiopro-
tector GL2011 almost completely prevented the suppres-
sive effect observed on day 30 post-irradiation. Namely, in 
respect to both the total number of bone marrow nucle-
ated cells, as well as to the CFU-F number per femur, the 
values determined in the Group I, ie, the irradiated ani-
mals treated with GL2011, showed no significant differ-
ence from either the drug-treated only (Group III) or 
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the non-irradied group without treatment (Group IV). The 
unchanged viability among groups at day 30 post-irradia-
tion indicates the consistency of the isolation technique 
and confirms that GL2011 is specific and efficient for re-
pairing the overall bone marrow cellularity, as well as the 
subpopulation of BM-MSCs
The BM-MSCs contain a high proliferative potential and 
ability for self-renewal and are essential for the regenera-
tion of the hematopoietic system following total body ir-
radiation. Although it has been previously shown that as 
compared to hematopoietic progenitors, mesenchymal 
progenitors are differentially sensitive to radiation (19), the 
mechanisms used by MSCs to survive radiation doses le-
thal to the hematopoietic system are poorly understood. 
Data reporting drug induced radioprotection indicated 
that the protective effects could be associated with the 
maturation stage, proliferation, and differentiation state 
or the alterations of the cell cycle of the progenitor cells 
(19,20). Our study demonstrated that the treatment with 
GL2011 provided almost complete recovery of the bone 
marrow cellularity and the frequency of the CFU-Fs 30 days 
post-irradiation. However, in order to differentiate the ra-
dioprotective from the regenerative role of GL2011 further 
studies are needed, both by exposing in vitro bone mar-
row cells to different irradiation doses, or by evaluating in 
vivo the recovery pattern of bone marrow tissue.
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